Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

被引：2

作者：

Melody, Megan ^{[1
]}

Epperla, Narendranath ^{[2
,3
]}

Shouse, Geoffrey ^{[4
]}

Romancik, Jason ^{[5
]}

Allen, Pamela ^{[5
]}

Moyo, Tamara K. ^{[6
]}

Kenkre, Vaishalee ^{[7
]}

Ollila, Thomas ^{[8
]}

Fitzgerald, Lindsey ^{[9
]}

Hess, Brian ^{[10
]}

David, Kevin ^{[11
]}

Herr, Megan M. ^{[12
]}

Odetola, Oluwatobi ^{[1
]}

Lin, Adam ^{[13
]}

Moreira, Jonathan ^{[13
]}

Ma, Shuo ^{[12
]}

Winter, Jane N. ^{[13
]}

Roy, Ishan ^{[14
]}

Stephens, Deborah ^{[15
]}

Danilov, Alexey

Shah, Nirav N. ^{[16
]}

Barta, Stefan K. ^{[17
]}

Cortese, Matthew ^{[12
]}

Cohen, Jonathon B. ^{[5
]}

Gordon, Leo I. ^{[13
]}

Karmali, Reem ^{[1
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, 676 N Saint Clair St,Suite 850, Chicago, IL 60611 USA

[2] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH USA

[3] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH USA

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[7] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[8] Brown Univ, Lifespan Canc Inst, Providence, RI USA

[9] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[10] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA

[11] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[12] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[14] Shirley Ryan Abil Lab, Chicago, IL USA

[15] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[16] Med Coll Wisconsin, MCW Canc Ctr, Milwaukee, WI USA

[17] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

来源：

BLOOD ADVANCES | 2024年 / 8卷 / 10期

关键词：

COMPOSITE LYMPHOMA; MULTICENTER; CANCER;

D O I：

10.1182/bloodadvances.2024012573

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2327 / 2331

页数：5

共 50 条

[1] Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Hsieh, Emily M.
Myers, Regina M.
Yates, Bonnie
Annesley, Colleen
John, Samuel
Taraseviciute, Agne
Steinberg, Seth M.
Sheppard, Jennifer
Chung, Perry
Chen, Lee
Lee, Daniel W.
DiNofia, Amanda
Grupp, Stephan A.
Verneris, Michael R.
Laetsch, Theodore W.
Bhojwani, Deepa
Brown, Patrick A.
Pulsipher, Michael A.
Rheingold, Susan R.
Gardner, Rebecca A.
Gore, Lia
Shah, Nirali N.
Lamble, Adam J.
BLOOD ADVANCES, 2022, 6 (17) : 5222 - 5226
[2] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
Zhang, Wen-ying
Liu, Yang
Wang, Yao
Nie, Jing
Guo, Ye-lei
Wang, Chun-meng
Dai, Han-ren
Yang, Qing-ming
Wu, Zhi-qiang
Han, Wei-dong
GENE THERAPY, 2018, 25 (03) : 198 - 204
[3] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
Wen-ying Zhang
Yang Liu
Yao Wang
Jing Nie
Ye-lei Guo
Chun-meng Wang
Han-ren Dai
Qing-ming Yang
Zhi-qiang Wu
Wei-dong Han
Gene Therapy, 2018, 25 : 198 - 204
[4] Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota, Victoria
Kerschbaum, Johanna Franziska
Penack, Olaf
Stein, Catarina M.
Arends, Christopher M.
Koenecke, Christian
Strzelecka, Paulina M.
Kloos, Arnold
Wiegand, Laura
Lasch, Alina
Altwasser, Robert
Halik, Adriane
Gabdoulline, Razif
Thomson, Julia
Weibl, Konstantin
Franke, Georg-Nikolaus
Berger, Carolina
Hasenkamp, Justin
Ayuk, Francis
Na, Il-Kang
Beutel, Gernot
Keller, Ulrich
Bullinger, Lars
Wulf, Gerald Georg
Kroeger, Nicolaus
Vucinic, Vladan
Heuser, Michael
Damm, Frederik
HEMASPHERE, 2023, 7 (10): : E957
[5] Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas
Giulia Losi
Alberto Mussetti
Marta Peña
Patricia Lopez-Pereira
Anna Sureda
Silvana Novelli
Bone Marrow Transplantation, 2025, 60 (3) : 259 - 269
[6] A safe and potent anti-CD19 CAR T cell therapy
Ying, Zhitao
Huang, Xue F.
Xiang, Xiaoyu
Liu, Yanling
Kang, Xi
Song, Yuqin
Guo, Xiaokai
Liu, Hanzhi
Ding, Ning
Zhang, Tingting
Duan, Panpan
Lin, Yufu
Zheng, Wen
Wang, Xiaopei
Lin, Ningjing
Tu, Meifeng
Xie, Yan
Zhang, Chen
Liu, Weiping
Deng, Lijuan
Gao, Shunyu
Ping, Lingyan
Wang, Xuejuan
Zhou, Nina
Zhang, Junqing
Wang, Yulong
Lin, Songfeng
Mamuti, Mierzhati
Yu, Xueyun
Fang, Lizhu
Wang, Shuai
Song, Haifeng
Wang, Guan
Jones, Lindsey
Zhu, Jun
Chen, Si-Yi
NATURE MEDICINE, 2019, 25 (06) : 947 - +
[7] A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying
Xue F. Huang
Xiaoyu Xiang
Yanling Liu
Xi Kang
Yuqin Song
Xiaokai Guo
Hanzhi Liu
Ning Ding
Tingting Zhang
Panpan Duan
Yufu Lin
Wen Zheng
Xiaopei Wang
Ningjing Lin
Meifeng Tu
Yan Xie
Chen Zhang
Weiping Liu
Lijuan Deng
Shunyu Gao
Lingyan Ping
Xuejuan Wang
Nina Zhou
Junqing Zhang
Yulong Wang
Songfeng Lin
Mierzhati Mamuti
Xueyun Yu
Lizhu Fang
Shuai Wang
Haifeng Song
Guan Wang
Lindsey Jones
Jun Zhu
Si-Yi Chen
Nature Medicine, 2019, 25 : 947 - 953
[8] Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
Tabbara, Nadeem
Gaut, Daria
Oliai, Caspian
Lewis, Tara
de Vos, Sven
LEUKEMIA RESEARCH REPORTS, 2021, 16
[9] Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies
Yang, Xingcheng
Wei, Jia
Zhou, Jianfeng
HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 821 - 834
[10] Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy
Strati, Paolo
Brandt, Amanda
Henderson, Jared
Westin, Jason
Nastoupil, Loretta J.
Al Zaki, Ajlan
Jallouk, Andrew P.
Adkins, Sherry
Shpall, Elizabeth J.
Kebriaei, Partow
Ramdial, Jeremy
Saini, Neeraj Y.
Ahmed, Sairah
Flowers, Christopher R.
Neelapu, Sattva S.
Hildebrandt, Michelle
BLOOD, 2023, 142

← 1 2 3 4 5 →